Analytical Data
-
Gene name
GPC2
- Application
-
Alternative Names
Cerebroglycan; Glypican Proteoglycan 2, Cerebroglycan Proteoglycan; Secreted glypican-2
-
Species
Human
-
Source
HEK293
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q8N158
-
Expression Region
Val338~Thr562
-
Molecular Weight
33&65kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GPC2 (Glypican-2) is a heparan sulfate proteoglycan that plays a crucial role in various developmental processes and has been implicated in several types of cancer. It is predominantly expressed in the nervous system and is known to influence cell signaling pathways, particularly in the context of neurodevelopment and tumor biology. Recent studies have highlighted GPC2 as a potential oncofetal antigen, which is overexpressed in certain tumors, including neuroblastoma, making it a target of interest for immunotherapeutic strategies. The development of GPC2 recombinant proteins is essential for advancing research into its biological functions and therapeutic applications. By producing these recombinant proteins, scientists can investigate GPC2's interactions with other molecules and its role in tumor progression. Additionally, these proteins can be utilized in the design of monoclonal antibodies or other immune-based therapies aimed at targeting and eliminating GPC2-expressing tumor cells. Understanding the molecular mechanisms underpinning GPC2's activity may open new avenues for cancer treatment and provide insights into its involvement in neurological disorders. This research is pivotal for elucidating the broader implications of GPC2 in both health and disease, with the ultimate goal of translating this knowledge into effective therapeutic options for patients.
